Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 8,510,000 shares, an increase of 28.5% from the January 31st total of 6,620,000 shares. Based on an average daily trading volume, of 13,950,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 11.2% of the company’s shares are short sold.

Invivyd Trading Up 11.7 %

Shares of IVVD traded up $0.11 during trading hours on Tuesday, reaching $1.05. The stock had a trading volume of 10,577,105 shares, compared to its average volume of 21,932,908. Invivyd has a 12 month low of $0.35 and a 12 month high of $4.74. The firm has a 50-day simple moving average of $0.89 and a 200 day simple moving average of $0.87. The company has a market capitalization of $125.60 million, a price-to-earnings ratio of -0.54 and a beta of 0.61.

Analysts Set New Price Targets

Several brokerages have recently commented on IVVD. Morgan Stanley reduced their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Invivyd in a report on Monday, February 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Invivyd in a report on Monday, February 24th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Invivyd presently has an average rating of “Buy” and a consensus price target of $7.89.

Insider Transactions at Invivyd

In other news, Director Terrance Mcguire sold 65,359 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73. Following the completion of the sale, the director now owns 4,012,320 shares of the company’s stock, valued at $1,885,790.40. This trade represents a 1.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 816,466 shares of company stock valued at $423,214 in the last quarter. 17.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Invivyd

Several large investors have recently bought and sold shares of the stock. Two Sigma Investments LP lifted its stake in Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after acquiring an additional 204,188 shares in the last quarter. Two Sigma Advisers LP lifted its stake in Invivyd by 1,276.5% during the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after acquiring an additional 282,100 shares in the last quarter. Mithril II GP LP bought a new position in Invivyd during the 4th quarter valued at $4,981,000. Deutsche Bank AG lifted its stake in Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock valued at $385,000 after acquiring an additional 227,463 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after acquiring an additional 87,358 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.